D-0165-2025 Class II Ongoing

Recalled by RemedyRepack Inc. — Indiana, PA

FDA drug recall D-0165-2025 was initiated by RemedyRepack Inc. on Dec 2, 2024 and is designated Class II. Reason for recall: CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit. The recall status is ongoing. Affected quantity: a) 1,564 cards, b) 799 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 1, 2025
Initiation Date
Dec 2, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 1,564 cards, b) 799 bottles

Product description

Duloxetine Delayed-Release Capsules, 60 mg, a) 30 count blister cards (NDC 70518-0937-04), b) 30 count bottles (NDC 70518-0937-03), Rx only, Source NDC 57237-0019-99, MFG: Rising Pharma, Inc., Allendale, NJ, Repackaged by: RemedyRepack Inc., Indiana, PA

Reason for recall

CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.

Distribution pattern

Nationwide in the US

Code information

a) NDC 70518-0937-04, Lot # J0786744-061724, Exp. 06/30/2025 b) NDC 70518-0937-03, Lot # B3002625-060524, Exp. 10/31/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0165-2025
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0165-2025. Report a data issue: hello@regdatalab.com.